{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension&page=31",
    "query": {
      "intervention": "Open Label Extension",
      "page": 31
    },
    "page_size": 10
  },
  "pagination": {
    "page": 31,
    "page_size": 10,
    "total_count": 2289,
    "total_pages": 229,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension&page=32&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension&page=30&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T22:07:52.224Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03299842",
      "title": "A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dravet Syndrome"
      ],
      "interventions": [
        {
          "name": "ZX008 (Fenfluramine Hydrochloride)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "2 Years to 35 Years"
      },
      "enrollment_count": 5,
      "start_date": "2017-07-12",
      "completion_date": "2018-07-05",
      "has_results": true,
      "last_update_posted_date": "2023-11-13",
      "last_synced_at": "2026-10-28T22:07:52.224Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Aurora, Colorado",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03299842"
    },
    {
      "nct_id": "NCT01355289",
      "title": "Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "Avatrombopag",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pegylated interferon (PEG-IFN)",
          "type": "DRUG"
        },
        {
          "name": "Telaprevir",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2011-11",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2018-02-22",
      "last_synced_at": "2026-10-28T22:07:52.224Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Fairfax, Virginia",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01355289"
    },
    {
      "nct_id": "NCT07041489",
      "title": "Evaluating the Combined Use of Supplement and Serum in Promoting Hair Growth in Women With Self-perceived Thinning Hair",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hair Thinning"
      ],
      "interventions": [
        {
          "name": "Active Comparator- Xtressé™ Supplement and Serum",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo Comparator- Placebo Supplement and Serum",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "The Center for Clinical and Cosmetic Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "28 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "28 Years to 65 Years · Female only"
      },
      "enrollment_count": 85,
      "start_date": "2025-05-20",
      "completion_date": "2026-03-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-27",
      "last_synced_at": "2026-10-28T22:07:52.224Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • Aventura, Florida",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07041489"
    },
    {
      "nct_id": "NCT01151098",
      "title": "Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Nonmalignant Pain"
      ],
      "interventions": [
        {
          "name": "Buprenorphine transdermal patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Purdue Pharma LP",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 189,
      "start_date": "2001-04",
      "completion_date": "2002-02",
      "has_results": true,
      "last_update_posted_date": "2012-09-10",
      "last_synced_at": "2026-10-28T22:07:52.224Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Trumbull, Connecticut • Clearwater, Florida + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Trumbull",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01151098"
    },
    {
      "nct_id": "NCT03802799",
      "title": "Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Fragile X Syndrome"
      ],
      "interventions": [
        {
          "name": "ZYN002 - Cannabidiol Transdermal Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zynerba Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "3 Years to 29 Years"
      },
      "enrollment_count": 476,
      "start_date": "2018-11-09",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-10-28T22:07:52.224Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Culver City, California • Irvine, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03802799"
    },
    {
      "nct_id": "NCT06663358",
      "title": "A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "Pegunigalsidase-alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chiesi Farmaceutici S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2024-11-06",
      "completion_date": "2029-11",
      "has_results": false,
      "last_update_posted_date": "2025-11-14",
      "last_synced_at": "2026-10-28T22:07:52.224Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06663358"
    },
    {
      "nct_id": "NCT00369343",
      "title": "Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Depression",
        "Depressive Disorder",
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 70 Years · Female only"
      },
      "enrollment_count": 381,
      "start_date": "2006-09",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2012-05-07",
      "last_synced_at": "2026-10-28T22:07:52.224Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Springdale, Arkansas + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00369343"
    },
    {
      "nct_id": "NCT04053543",
      "title": "CXA-10 Study in Subjects With Pulmonary Arterial Hypertension",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "PAH"
      ],
      "interventions": [
        {
          "name": "CXA-10",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Complexa, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2019-08-09",
      "completion_date": "2020-08-12",
      "has_results": false,
      "last_update_posted_date": "2020-08-26",
      "last_synced_at": "2026-10-28T22:07:52.224Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04053543"
    },
    {
      "nct_id": "NCT07573176",
      "title": "A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "Seltorexant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 600,
      "start_date": "2026-04-30",
      "completion_date": "2029-05-03",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-28T22:07:52.224Z",
      "location_count": 34,
      "location_summary": "Bryant, Arkansas • Bellflower, California • Glendale, California + 27 more",
      "locations": [
        {
          "city": "Bryant",
          "state": "Arkansas"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07573176"
    },
    {
      "nct_id": "NCT02096952",
      "title": "Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention-deficit/Hyperactivity Disorder",
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Methylphenidate extended-release liquid formulation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 15,
      "start_date": "2014-05",
      "completion_date": "2018-01",
      "has_results": true,
      "last_update_posted_date": "2024-07-01",
      "last_synced_at": "2026-10-28T22:07:52.224Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02096952"
    }
  ]
}